ATC OnDemand is your online portal to educational information from a variety of sessions from the American Transplant Congress. This portal allows you to view Congress sessions virtually and includes speaker handouts, audio streaming presentations, MP3 downloadable files and so much more.
2015 Cutting Edge of Transplantation - Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
CEOT 2015 brought together leading clinicians and scientists from academia and industry, from within and outside the field of transplantation, to discuss the current and future challenges in transplantation with a focus on cell engineering, gene, and drug therapies.
This symposium is designed for and limited to clinical fellows and residents, surgical fellows, research fellows, pharmacists and other trainees who are planning a career in transplantation medicine, surgery, or research.
The topic of CEOT 2014 was "Optimizing Long-Term Transplant Survival: Therapeutics, Targets, Technologies" and featured a renowned faculty of experts.
View select sessions from the first Cutting Edge of Transplantation: "B Cells from Bedside to Bench to Bedside: A Comprehensive Look at B Cells and Antibodies in Transplantation."
Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.